Metformin for gestational diabetes in routine clinical practice.

Area of Science:

• Obstetrics and Gynecology
• Perinatology
• Endocrinology

Background:

• Gestational diabetes mellitus (GDM) requires careful management to mitigate maternal and neonatal complications.
• Treatment options for GDM include diet, metformin, and insulin, each with potential varying outcomes.
• Understanding comparative effectiveness in routine clinical practice is crucial for optimizing GDM care.

Purpose of the Study:

• To compare maternal and neonatal outcomes of gestational diabetes mellitus (GDM) managed with diet, metformin, and/or insulin.
• To evaluate treatment effectiveness in a real-world clinical setting.

Main Methods:

• Prospective data analysis of 1269 women with GDM delivering between January 2007 and December 2009.
• Comparison of outcomes across three treatment groups: diet, insulin, and metformin (alone or with insulin).
• Exclusion of women with fetal abdominal circumference <10th percentile from metformin treatment.

Main Results:

• Women on metformin/insulin had higher BMIs and fasting glucose at diagnosis compared to diet-only.
• Insulin treatment was associated with higher rates of Cesarean delivery, preterm birth, large-for-gestational-age infants, neonatal admissions, and dextrose use.
• Neonatal outcomes were comparable between women treated with diet and metformin.

Conclusions:

• Metformin use in GDM appears associated with fewer adverse maternal and neonatal outcomes compared to insulin in routine practice.
• Baseline differences in patient characteristics between treatment groups may confound the observed outcomes.
• Further research is needed to confirm metformin's benefits and understand confounding factors in GDM management.